SPY772.74−0.58%QQQ747.02−1.41%BTC/USD81,275.07−2.40%DIA510.77−0.05%GLD378.29+0.64%TLT77.81+0.86%
Benzinga

Stock Trading Ideas

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Webull Just Exposed a Bigger China Risk for Futu and UP Fintech
Webull Just Exposed a Bigger China Risk for Futu and UP Fintech
QUICK SPARK: Chipotle Stock Eyes Best Day Since July on Starbucks' Takeover Interest
QUICK SPARK: Chipotle Stock Eyes Best Day Since July on Starbucks' Takeover Interest
Webull Just Exposed a Bigger China Risk for Futu and UP Fintech
Webull Just Exposed a Bigger China Risk for Futu and UP Fintech
QUICK SPARK: Chipotle Stock Eyes Best Day Since July on Starbucks' Takeover Interest
QUICK SPARK: Chipotle Stock Eyes Best Day Since July on Starbucks' Takeover Interest
Spotify Won't Let Go of Joe Rogan, Podcast King Secures Another Multiyear Deal
Spotify Won't Let Go of Joe Rogan, Podcast King Secures Another Multiyear Deal
Why Is Unity Software Stock Gaining Thursday?
Why Is Unity Software Stock Gaining Thursday?

Trading Ideas Recent News

AngioDynamics Stock Is Falling Thursday: What's Going On?
AngioDynamics Stock Is Falling Thursday: What's Going On?
ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.
What Is Going on with AppLovin Stock on Thursday?
What Is Going on with AppLovin Stock on Thursday?
AppLovin stock dips as investors weigh a San Diego child privacy lawsuit and competition against new high-quality advertiser partnerships.
QUICK SPARK: Trump Says US Will Not Attack Iran Before Midterm Election
QUICK SPARK: Trump Says US Will Not Attack Iran Before Midterm Election
President Donald Trump rules out U.S. military action against Iran before the Nov. 3 midterm elections.
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.
AI Monetization Moat: Meta Leverages Social Engagement to Offset Rising Infrastructure Spending
AI Monetization Moat: Meta Leverages Social Engagement to Offset Rising Infrastructure Spending
Meta Platforms stock holds steady as investors balance high Q3 revenue expectations, strong user engagement against rising capital expenditure projections.
These Analysts Revise Their Forecasts On Applied Digital Following Q1 Results
These Analysts Revise Their Forecasts On Applied Digital Following Q1 Results
Applied Digital beat Q1 estimates with $300.4M revenue and a 1-cent adjusted loss; analysts mixed on targets as shares fell 1.4%.
Bitcoin Slide Meets 5.7% Bond Yields: Neoclouds Get Hit From Both Sides
Bitcoin Slide Meets 5.7% Bond Yields: Neoclouds Get Hit From Both Sides
Neocloud stocks like IREN and Nebius face falling crypto prices, rising borrowing costs and sharp stock declines.
Delta Air Lines Q3 Preview: Stock Gains Since Iran War Rare for Sector, Will They Continue?
Delta Air Lines Q3 Preview: Stock Gains Since Iran War Rare for Sector, Will They Continue?
As other airline stocks fall since the Iran War began, Delta Air Lines stock is up. Will this continue after Q3 results?
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved